Paratek Pharmaceuticals, Inc.

NasdaqGM:PRTK Stock Report

Market Cap: US$127.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Paratek Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 1/6

Paratek Pharmaceuticals has a total shareholder equity of $-201.4M and total debt of $258.3M, which brings its debt-to-equity ratio to -128.3%. Its total assets and total liabilities are $145.8M and $347.2M respectively.

Key information

-128.3%

Debt to equity ratio

US$258.33m

Debt

Interest coverage ration/a
CashUS$42.69m
Equity-US$201.36m
Total liabilitiesUS$347.16m
Total assetsUS$145.79m

Recent financial health updates

No updates

Recent updates

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Apr 17
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Paratek Pharmaceuticals: Patience Is Wearing Thin

Aug 24

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Aug 03

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

Jan 03

The Play On Paratek Pharmaceuticals

Oct 18

Peeking Back In On Paratek Pharmaceuticals

Aug 07

Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial

Jun 16

Paratek shares rise after FDA approves NUZYRA oral only dosing regimen

Jun 01

Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business

Apr 27

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Mar 01
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Feb 01
Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment

Jan 04

Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale

Dec 01

Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Financial Position Analysis

Short Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PRTK has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PRTK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PRTK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PRTK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies